Bioconjugates synthetic polypeptide apelin

It relates to bioconjugates which comprise: a) a peptide or polypeptide of formula I ', wherein X1 is absent or is selected from R, Q, A, K, among others; X2 is R, A, K, M, F, E, among others; X3 is P, A, K, D, among others; X4 is R, A, F, E, among others; X5 is L, A, K, D, F, among others; X6 and X12 are independently C, K, D, Orn, Dab, E, among others, where X6 and X12 are linked through a covalent bond -S-, -SS-, -NHC (O) - or -C ( O) NH-; X7 is H, A, Aib, K, Nal, F, P, Dap, N, E, among others; X8 is K, F, A, E, among others; X9 is G, A, D, L, R, among others; X10 is P, A, 4-PhP, among others; X11 is M, Nle, L, F, Y, L, K, among others; and X13 is absent or selected from F, Nal, F, I, A, K, H, E, among others; b) a fraction of extension of half-life, fused or covalently attached through a linker to the peptide or polypeptide of formula I '. In a preferred aspect, the fraction extender is a half-life of IgG constant domain or fragment thereof, or human serum albumin. Also it relates to pharmaceutical compositions comprising these bioconjugates, and combinations thereof with one or more therapeutically active co-agents such as inotropes, beta-blockers adrenergic receptors, among others. Such conjugates are useful in the treatment or prevention of heart failure, atherosclerosis, hypertension, arrhythmia, obesity, etc.